Not medical advice. CJC-1295 (with DAC) is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
CJC-1295 (with DAC) is listed in our catalogue under “HGH / Somatropin.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
CJC-1295 DAC, long-acting GHRH analogue with maleimidopropionic acid Drug Affinity Complex enabling covalent albumin binding and 6–8 day half-life.
Peer-reviewed literature typically discusses CJC-1295 (with DAC) in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1–2 mg subcutaneously · Once or twice weekly due to extended 6–8 day half-life · Terminal t½ = 5.8–8.1 days; albumin bioconjugation occurs within 15 min post-injection; GH elevation persists ≥6 days; IGF-1 elevation persists 9–11 days after single dose; steady-state IGF-1 with repeated dosing at 28 days. No-DAC variant has ~30 min half-life for comparison.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) with four amino-acid substitutions that resist enzymatic breakdown. It activates the pituitary GHRH receptor to drive growth-hormone release. This DAC version adds a "Drug Affinity Complex" tag that binds serum albumin, extending its half-life to ~6-8 days. Supplied as a lyophilised research-grade powder for laboratory use only.
In research models CJC-1295 binds the GHRH receptor on the pituitary and stimulates the release of growth hormone, which in turn raises IGF-1. The DAC tag sustains that signal for days rather than minutes. These are findings in cell and animal models; no human therapeutic effect is implied.
In published animal studies CJC-1295 has generally been well tolerated, but there are no controlled human safety trials, so human safety is not established. It is a research compound, not a medicine; New-U makes no human-use claims and supplies it for laboratory research only.
No. CJC-1295 is an investigational research peptide and is not approved by the FDA, EMA, or any other regulator for human therapeutic use. It is sold strictly for preclinical and in-vitro research.
DAC stands for "Drug Affinity Complex". It is a small chemistry tag - specifically maleimidopropionic acid - attached to the C-terminal lysine of the peptide. When you inject the peptide, the DAC reacts with the free thiol of cysteine-34 on serum albumin, forming a covalent bond. The peptide then piggy-backs on albumin for days.
Both share the same tetrasubstituted GHRH(1-29) backbone. The DAC version carries the albumin-binding tag and lasts ~6-8 days; the no-DAC version (often called Modified GRF 1-29) has no DAC tag and lasts roughly 30 minutes. DAC is used for sustained elevation; no-DAC is used for physiologic pulses.
GHRH analogs like CJC-1295 and ghrelin-receptor agonists like ipamorelin hit two different receptors (GHRHR and GHSR) that synergise in GH release. Combining them produces larger, cleaner GH pulses than either peptide alone, which is why this is a standard research pairing.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The DAC chemistry is relatively stable once the peptide is in solution, but plan dosing to use reconstituted material within the standard peptide-stability window.
CJC-1295 is a GHRH analogue that stimulates the pituitary's own GH release rather than replacing a hormone. In the research literature, ending administration returns the GH/IGF-1 axis toward its untreated baseline; the DAC form's albumin binding means it clears over a week or more, so the stimulus tapers gradually rather than stopping instantly. Unlike exogenous HGH, no axis-shutdown rebound is described. These are research-model observations — CJC-1295 DAC is supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside CJC-1295 (with DAC).
Primary literature and registries for CJC-1295 (with DAC), plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: CJC-1295 with DAC, DAC:GRF, Drug Affinity Complex GRF, CJC-1295 DAC, Modified GRF 1-29 with DAC, ConjuChem GRF